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Abstract
Noncoding genomics, i.e., microRNAs and long coding RNAs (lncRNA), is an 
emerging topic in gastrointestinal tumors. In particular, the coordinate deregula-
tion of miRNA-335-5p across these tumors and its potential clinical applications 
is an example of this scenario. This chapter discusses the pathogenetic role of 
miRNA-335-5p in esophageal, gastric, colon, liver, gallbladder, and pancreatic 
tumors. This pathogenetic role is examined in the context of the competing 
endogenous network, the language through lncRNA that reduce the quantity 
of miRNA available to target mRNA. The translational application of miRNA-
335-5p, through the aberrant methylation of the promoter region of MEST—its 
host gene—as a potential biomarker for noninvasive detection of gastric cancer, 
is also discussed.
Keywords: ncRNA, miRNA-335-5p, gastrointestinal tumors, gastric cancer, 
competing endogenous, CERNA, DNA methylation, biomarkers
1. Introduction
Gastrointestinal tumors (i.e., esophagus, stomach, colon, liver, gallbladder, 
and pancreas) are among the most common cancers by incidence and mortality 
in males and females worldwide [1]. Furthermore, projections of global mortal-
ity and disease burden indicate that new cases and deaths from these tumors 
will increase by 2030 [2]. Given this scenario, understanding of the molecular 
basis of gastrointestinal tumors is essential to the development of novel strate-
gies for diagnosis and disease treatment. Large genomic studies focusing on 
protein-coding regions have identified multiple of genes recurrently mutated in 
gastrointestinal and other human neoplasms [3]. However, molecular classifica-
tions based on coding genes do not fully capture the clinical heterogeneity found 
in gastrointestinal tumors [4]. This observation indicates that other segments of 
the genome might also contribute to the emerging complexities observed in the 
development and progression of gastrointestinal neoplasms. In this chapter, we 
describe recent advances in our understanding of noncoding genome in gastroin-
testinal cancer. In particular, we will focus on miRNA-335-5p, since not only has it 
been found to be critically involved in myriad tumors but it has also proved to be a 
potential biomarker for noninvasive diagnosis of cancer and for the treatment of 




The traditional view of the unidirectional flow (i.e., DNA-RNA-protein) of 
genomic data has been reclassified as multidirectional, based on the fact that even 
though 80% of DNA is transcribed into RNA, only 2% ultimately represent the 
coding genes which are translated into protein [7]. Therefore, the majority of RNA 
is defined as noncoding RNA (ncRNA) which in turn includes a wide range of 
RNA families such as those involved in the translation and splicing of messenger 
RNA (mRNA) as well as those associated with the modification of ribosomal RNA 
[7]. ncRNA also plays an essential role in all multiple biological functions, i.e., 
cell proliferation, apoptosis, cell migration and invasion, and cell differentiation 
being involved in each of the cancer hallmarks as well [8]. Based on the size of its 
sequence, ncRNA can be divided into short (~20–200 nucleotides; nt) and long 
ncRNA (200 to ~100,000 nt) [9].
2.1 Short noncoding RNAs
Short ncRNAs (sncRNAs) are represented by P-element-induced wimpy tes-
tis (PIWI)-interacting RNAs (piRNAs), small interfering RNAs (siRNAs), and 
microRNAs (miRNAs). piRNAs (24–32 nt) are specialized for repression of mobile 
and other genetic elements in germ line cells (e.g., LINE1 piRNAs and piR-823) 
[10]. piRNAs and PIWI have been found deregulated in a tissue-specific manner 
in a variety of neoplasms, opening novel opportunities to diagnosis and treatment 
of disease [10]. siRNAs regulate posttranscriptional gene silencing and the defense 
against pathogen nucleic acids (e.g., L1-specific siRNA and oocyte endo-siRNAs) 
[11]. Therefore, they seem to have great potential in disease treatment, especially as 
promising epigenetic therapy through the silencing of cancer-related genes [12].
miRNAs represent the largest group of short noncoding RNAs, highly conserved 
and involved in the posttranscriptional regulation of gene expression in multicel-
lular organisms [13]. miRNAs were discovered in the 1990s while studying fetal 
development of Caenorhabditis elegans [14]. To date, more than 30,000 miRNAs 
have been found in over 200 species [15]. In humans, the latest miRNA database 
miRBase release (Release 22.1) contains 2588 annotated mature miRNAs [15]. It is 
estimated that 60% of coding genes may be regulated by miRNAs. miRNAs have 
been found deregulated in a tissue-specific manner in human neoplasms, offering 
novel opportunities for diagnostic assessment and disease treatment [16].
Functional studies have confirmed critical roles of miRNAs in development 
and disease, particularly in cancer [17]. miRNAs can act as tumor suppressors or 
oncogenes, and miRNA mimics have shown promise in preclinical and early stages 
of clinical development [17]. miRNAs reflect the developmental lineage and dif-
ferentiation state of the tumors being mostly downregulated compared with normal 
counterpart tissues [18]. Particularly, gastrointestinal tumors cluster together 
reflecting their common derivation from embryonic endoderm [18]. miRNA-335-5p 
is among the most frequently deregulated miRNAs in gastrointestinal tumors.
2.2 miRNA-335-5p structure and regulation of its expression
Although initially described in developmental biology, as differentially 
expressed and maternally imprinted during mouse and human lung develop-
ment [19], later studies have shown that miRNA-335-5p is extensively deregulated 
in human tumors [20]. miRNA-335-5p is a transcript located on chromosome 
7q32.2, in the second intron of the mesoderm-specific transcript homolog (MEST) 
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gene [21], which encodes 17 different mRNAs [22]. In humans, the mature 
sequence of miRNA-335-5p forward strand, miRNA-335-5p, corresponds to 
16 -UCAAGAGCAAUAACGAAAAAUGU-38 (http://www.mirbase.org, accession: 
MIMAT0000765, ID: hsa-miR-335-5p) [23]. The strong correlation between the 
expression of miRNA-335-5p and its host gene MEST suggests that the mechanism 
responsible for silencing miRNA-335-5p expression should be the promoter meth-
ylation of MEST [5, 24, 25] (Figure 1). The promoter of MEST gene contains three 
CpG islands upstream of transcriptional start site [26]. The treatment with 5-aza-
2′-deoxycytidine (5-aza-dCyd) restores the expression levels of miRNA-335-5p 
in hepatocellular and gastric cancer [24, 27]. Furthermore, an inverse correlation 
between expression levels of miRNA-335-5p and its methylation status was revealed 
in these cancer tissues [24, 27].
2.3 miRNA-335-5p and gastrointestinal malignancies
The coordinated deregulation of miRNA-335-5p across the gastrointestinal tract 
neoplasms implied the relevant role of this microRNA in these tumors. Esophageal 
adenocarcinoma (EAC) is one of the fastest rising incidences of cancers with a 
dismal prognosis [28]. EAC is the final stage of Barrett esophagus (BE), an adaptive 
response to chronic gastroesophageal reflux in which the squamous epithelium of 
the esophagus is replaced by glandular columnar epithelium [28]. By combining 
multidimensional genomic measurements from the TCGA, Xi and Zhang [29] 
proposed a genomic signature of five differentially expressed miRNAs including 
miRNA-335-5p that can be applied for novel diagnostic approaches and disease 
treatment. Gastric cancer (GC) remains the fifth cause in cancer incidence and 
the third cause of death by neoplasms worldwide [1]. GC is a highly heterogeneous 
disease with unique ethnogeographical associations [30–32]. Profiling studies 
have not identified miRNA-335-5p as part of any miRNA signatures with  clinical 
significance. However, gene-specific approaches suggest that miRNA-335-5p is 
downregulated in GC and clinically associated with advanced TNM stage and worse 
prognosis [5, 33]. Functional studies have shown that exogenous expression of 
miRNA-335-5p deregulated many biological cell processes such as cell cycle, prolif-
eration, apoptosis, migration, invasion, and metastasis [5, 25, 33, 34] (Figure 2). 
Figure 1. 
Linear regression model (blue line) using RNAseq data from 368 tumor samples from the stomach 




Of note, upregulation of miRNA-335-5p might be associated with tumor recurrence, 
the major factor of treatment failure in this disease [35].
Colorectal carcinoma (CRC) is the first cause of death by cancer in developed 
countries [1]. In this tumor downregulation of miRNA-335-5p has been associated 
with microsatellite instability (MSI) [36] and ability to discriminate between non-
serrated and serrated adenomas [37]. Even though it has been described as upregu-
lated in tumor samples relative to normal mucosa, functional studies have shown 
that its overexpression inhibits invasion and metastasis in CRC cell lines [38, 39]. 
The number of deaths for hepatocellular carcinoma (HCC) is nearly equal to the 
worldwide annual incidence of newly diagnosed cases [40]. Almost 80% of HCC 
is attributed to chronic hepatitides B and C which evolve to cirrhotic/fibrotic liver 
and ultimately HCC [41]. Screening of multiple miRNAs identified miRNA-335-5p 
among unique seven miRNA signatures that could be associated with the develop-
ment HBV-related HCC [42]. Gallbladder carcinoma (GBC) is an infrequent but 
highly lethal biliary tract tumor mostly associated with the presence of gallstones and 
chronic inflammation [43]. Tumor suppressor and cancer-prone miRNAs have been 
identified in GBC including the downregulation of miRNA-335-5p, which together 
with other microRNAs produces a signature clinically associated with prognosis and 
prediction of treatment response [44]. Gene-specific analysis in paired tumor and 
normal tissues also confirms downregulation of miRNA-335-5p in association with 
histologic grade, stage, presence of metastases, and poor survival [45].
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, and 
because of the late presentation, as few as 20% of patients are candidates for cura-
tive treatment. Ectopic expression of miRNA-335-5p in pancreatic cancer cell lines 
significantly suppressed cell growth by inhibiting c-Met [46]. Other malignancies 
in which miRNA-335-5p is deregulated have been comprehensively described Luo 
et al. [20].
Figure 2. 
Cellular processes by which miRNA-335-5p contributes to their regulation though of different target genes in 
gastric cancer cell lines. miRNA-335-5p inhibits tumorigenicity, cell cycle, proliferation, apoptosis, migration, 
invasion, and metastasis [5, 25, 33, 34]. Abbreviations: CRKL, V-crk avian sarcoma virus CT10 oncogene 
homolog-like; CDH11, cadherin 11; PLAUR, plasminogen activator urokinase receptor; SP1, specificity protein 
1; BCL-w, BCL2-like 2 (taken from Sandoval-Bórquez et al. [5] with permission).
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2.4 Long noncoding RNAs and the competing endogenous network of miRNA-
335-5p in gastrointestinal malignancies
Long ncRNAs, which span from 200 to ~100,000 nt, make up the largest portion 
of the human noncoding transcriptome [47]. lncRNAs are essentially regulatory 
molecules implicated in multiple cellular processes in a tissue-specific manner 
[48]. Multiple reports have compiled the emerging role of the deregulated expres-
sion of lncRNAs in human tumors, and based on tissue-specific transcription, 
this novel class of genes holds strong potential as biomarkers and new therapeutic 
opportunities in cancer [49–52]. lncRNAs reduce the quantity of miRNA available 
to target mRNA (i.e., “sponges”), through the miRNA response elements (MREs) 
contained within the lncRNA and the 3′UTR of mRNA, which serve as miRNA-
binding sites [53]. Based on the relevance of these interactions, a new language has 
been proposed—the competing endogenous RNA (CERNA)- [52]. In the case of 
miRNA-335-5p, few CERNA networks have been described, which indicate that this 
is an emerging area of research in gastrointestinal tumors. As shown in Table 1, the 
lncRNA nuclear-enriched abundant transcript 1 (NEAT1) facilitates Sora resistance 
in HCC cells via negative regulation of miRNA-335/c-Met/Akt pathway that sup-
presses apoptosis [54]. The misato family member 2 (MSTO2P) has shown a high 
expression in parallel to a significantly low expression of miRNA-335-5p in clinical 
samples as well as in vitro [55]. As of this publication, no mRNA targets for this net-
work have been described. Nuclear-enriched abundant transcript 1 (NEAT) is also 
upregulated in GC and promotes proliferation, migration, and invasion via target-
ing the miRNA-335-5p/ROCK1 axis [56]. The zinc finger E-box binding homeobox 1 
antisense RNA 1 (ZEB1-AS1) has shown to be critical for the proliferation and inva-
sion of GC cells by regulating miRNA-335-5p [57]. However, the mRNAs associated 
with this CERNA network are currently unknown.
Further characterization of CERNA networks associated with the deregulation 
of miRNA-335-5p could be taken from the comprehensive evaluation of genes 
involved in metastasis and tumor invasion pathways after exogenous miRNA-335-5p 
expression [5]. Through this experiment up to 19 out of 62 (30.6%) genes were 
significantly increased [5]. Of note, miRNA-335-5p can target several messenger 
RNAs, and deregulation of miRNA-335-5p can effectively affect multiple signaling 
pathways leading to metastasis and tumor invasion [58]. In this scenario, ingenu-
ity pathway analysis (IPA) narrowed the field to nine upregulated genes (CDH11, 
COL4A2, CTGF, CTSK, MMP7, PDGFA, PLAUR, TIMP1, and TIMP2) (Figure 3). 
Most of these upregulated genes belong to intracellular signaling pathways in cancer 
such as PI3K-Akt (COL4A2, MYC, PDGFA, SPP1), proteoglycans (HIF1A, MYC, 
PLAUR, TGFB1), and Hippo (CTGF, MYC, NF2, TGFB1). Among these genes, 
PLAUR significantly increased mRNA levels after knockdown of miRNA-335-5p 
expression in GC cells. PLAUR is a membrane-bound glycoprotein with a GPI 
anchor that encodes the receptor of urokinase-type plasminogen activator and 
binds and activates PLAU [59]. This activated serine protease converts plasminogen 
to plasmin, degrading all components of the extracellular matrix and promot-
ing invasion and metastasis [60]. Furthermore, PLAUR has signaling properties 
through interactions with membrane-bound integrins, which are able to affect 
migration and cell proliferation [61]. In GC, the overexpression of PLAUR has 
been reported to be closely related to cell invasion and metastasis [62, 63]. In vitro 
analysis also showed a significant increase of PLAUR expression in miRNA-335-5p 
knockdown cells, and, consequently, cells overexpressing miRNA-335-5p exhibited 
a low level of PLAUR. Accordingly, elevated levels of PLAUR were observed in 
tumor tissues when compared with their paired non-tumor mucosa [5]. Another 










lncRNA name ID Abbreviation Target coding gene Topic Validation Reference
Nuclear-enriched abundant transcript 1 ENSG00000245532 NEAT1 c-Met Hepatocellular carcinoma In vitro/in vivo Chen and Xia [54]
Misato family member 2, pseudogene ENSG00000203761 MSTO2P Unknown Gastric cancer/metastasis Clinical/in vitro Li et al. [55]
Nuclear-enriched abundant transcript 1 ENSG00000245532 NEAT1 ROCK1 Gastric cancer Clinical/in vitro Wang et al. [56]
ZEB1 antisense RNA 1 ENSG00000237036 ZEB1-AS1 Unknown Gastric cancer Clinical/in vitro/in vivo Zhang et al. [3, 57]
Table 1. 
Competing endogenous RNA (CERNA) associated to miR-335-5p.
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CDH11, which encodes a type II classical cadherin, an integral membrane protein 
that mediates calcium-dependent cell-cell adhesion [64]. CDH11 has been reported 
as deregulated in various tumor types, suggesting a role in metastasis and tumor 
invasion [65, 66], and its overexpression was found in advanced cases of gastric 
cancer [67]. Binding experiments demonstrate the presence of direct targeting of 
miRNA-335-5p in the CDH11 gene [5]. Interestingly, preliminary data of potential 
targets of miRNA-335-5p in association with PLAUR and/or CDH11 reveal 15,898 
new lncRNAs or 27,688 transcripts for further exploration of the role of CERNA in 
metastasis and tumor invasion pathways.
2.5 Translational applications of miRNA-335-5p
Methylated cell-free DNA in plasma has emerged as a potential biomarker for 
diagnosis, prognosis, and prediction of treatment response in gastrointestinal 
tumors [24, 68]. In addition, several studies have shown that downregulation of 
miRNAs is associated with DNA methylation of the promoter region of its host 
genes [69].
Envisaging the clinical application of the downregulation of miRNA-335-5p 
in GC, Sandoval-Bórquez et al., [5] expand to plasma the reported inverse 
correlation between the expression of miRNA-335-5p and aberrant promoter 
methylation of its host gene (MEST) in tissues and cell lines [24] (Figure 4A). 
Furthermore, these authors demonstrated that this aberrant hypermethylation 
could be a surrogate biomarker for noninvasive diagnosis of GC since it was 
significantly found in GC cases in comparison with healthy donors (p = 0.029, 
Pearson’s correlation) (Figure 4B).
Figure 3. 
Ingenuity pathway analysis (IPA) for network enrichment analysis identified metastasis and invasion 
downstream genes of miRNA-335. A network of nine significantly overexpressed (red) genes during miRNA-
335 inhibition. The MAP tool shows activation and inhibition of neighboring genes and predicts activation of 




In this review, we summarize the role of miRNA-335-5p in gastrointestinal 
tumors with a focus on GC. We also explored the role of miRNA-335-5p in noncod-
ing and coding gene networks and its downstream signaling pathways involved 
in the biological effects of tumor growth, invasion, and metastasis. This evidence 
supports the potential use of miRNA-335-5p in noninvasive diagnosis as well as 
therapeutic prospects in gastrointestinal cancers.
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Figure 4. 
Potential clinical application as noninvasive detection of GC by the downregulation of miRNA-335-5p. In (A) 
expression of miRNA-335-5p in plasma from GC patients and healthy donors by Cq of miRNA-335-5p, data 
were transformed to logarithmic values (−log), and results indicate the mean ± SD. In (B) methylation-specific 
PCR of the promoter region of MEST gene in plasma from GC patients and healthy donors, MyoD was used 
as a control of DNA conversion. MW, weight marker; M, PCR product with primers specific for methylated 
promoter region of MEST, host gene of miRNA-335-5p; PC, positive control of methylation (methylated GC 
cell line); NC, negative control of methylation (peripheral blood lymphocytes) (taken from Sandoval-Bórquez 
et al. [5] with permission).
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